Navigation Links
New Webinar Hosted by Xtalks Prepares Manufacturers for AMNOG Regulations and the Future of Access and Pricing
Date:8/25/2014

Toronto, Canada (PRWEB) August 25, 2014

Introduction of the Pharmaceutical Market Restructuring Act (AMNOG) in 2011 and the resulting requirements for benefit assessment have fundamentally changed the conditions of market access and pharmaceutical pricing in Germany. The aim of this mandatory evaluation of clinical evidence was to limit the cost of pharmaceuticals and tackle the price monopoly of drug manufacturers in Germany.

While this has successfully been achieved, it has also brought with it further implications beyond the immediate German market, particularly for those countries that use Germany as a price reference. The open nature in which the clinical evidence and especially the critical aspects in these assessments is shared publically has potential impact on a product’s value story with payers in many other jurisdictions. For organizations working in this market or utilizing German price points for market access strategy, understanding these interconnections is critical.

Key take aways of this program include:

  •     Understanding of current AMNOG process
  •     Implications of AMNOG evaluation
  •     Impact of publically available assessment on value story
  •     Overview of price discount trends, both average and unique examples
  •     Future growth beyond current AMNOG framework

For more information or to register for this webinar, visit: AMNOG – German Regulation in the Past, Present and Future.

About Xcenda and Herescon
Xcenda is a strategic co
'/>"/>

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks
2. Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks
3. Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks
4. China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks
5. The Voice of the Patient in Clinical Trials: Hearing It, Understanding It, New Webinar Hosted by Xtalks
6. Protocol Pooling and Point of Distribution (PoD) Clinical Labeling, Live Webinar Hosted by Xtalks
7. Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks
8. The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks
9. Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks
10. Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks
11. Implementing Risk-based Monitoring, Using Oncology Examples, New Webinar July 31st Hosted by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed ... Medical Technologies Summit in San Francisco to take first ... among Silicon Valley investors and technology elites as the ... also positions Briteseed to move on to the ... and compete with other elite innovation finalists for a ...
(Date:11/22/2014)... Nov. 21, 2014  The element of surprise has ... i.e., they strike without warning. Until now, epidemiologists had ... a viral outbreak, resulting in suboptimal responses to both ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... been removed because virus gene structural changes have been ...
(Date:11/21/2014)... --  TRU-D SmartUVC LLC and its UK partners, Rapid ... robot, TRU-D SmartUVC, at FIS 2014 in Harrogate, ... at Stand 23. The conference, hosted by Federation ... largest infection-related event of its kind and brings together ... leading events of its type throughout the world. This annual ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 Author Matthew ... Walk to the Other Side” published as a ... Finalist in the “Fiction: Short Story” category of the ... Keen, President and CEO of USA Book News, said ... and independent publishers, including Simon & Schuster, Penguin, John ...
Breaking Biology Technology:Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Viruses' Advantage of Surprise is Lost 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4
... , MISSISSAUGA, ON, Nov. 23 /PRNewswire-FirstCall/ - YM ... a life sciences product development company that identifies and ... various stages of development, today reported that Cytopia (ASX:CYT) ... CYT387, a potent, orally-administered JAK1/JAK2 inhibitor. The trial is ...
... , BURNABY, BC, Nov. 23 /PRNewswire/ - Inimex Pharmaceuticals, Inc. ... as its President and CEO. , Abrams brings more than ... He is a co-inventor of the nuclear medicine imaging agent, ... plc where he was Manager, Biomedical Research Worldwide. In 1996, ...
... , , , , , , ... , , AUDIO: ... , Click here for more information. , ... , , , , ...
Cached Biology Technology:YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 5Inimex Announces Appointment of New CEO 2Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure ... Industry Association today jointly announce the formation of ... release of its Identity and Biometric Entry ... The Framework received official support from BORDERPOL, the ... to improve and provide expertise regarding border security, ...
(Date:11/15/2014)... , Nov. 13, 2014  While we may still be ... McCoy used in "Star Trek" to gain instant access to ... to work with smartphones and tablets for monitoring and measuring ... healthcare world. This may seem a tad Orwellian to some, ... adopt some of these technological opportunities into their healthcare regime. ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... Researchers at Woods Hole Oceanographic Institution (WHOI) have developed ... represent the acoustic equivalent of the leap from black-and-white ... mean a major upgrade in their ability to count ... seas of turbulence. Lead authors Tim Stanton and ...
... limped off the pitch, thereby ending his chances of ... injuries and rehabilitation techniques were once again front and ... to one player,s Achilles tendon is a sign of ... of research. Now Paul Comfort and Earle Abramson,s pioneering ...
... reagents have been developed for C. Elegans micro RNA. ... Silence have created the first class of reagents ... used model organism. Wen-hong Li, from the University ... team of researchers including Dr. Genhua Zheng and Dr. ...
Cached Biology News:Now in broadband: Acoustic imaging of the ocean 2Now in broadband: Acoustic imaging of the ocean 3Now in broadband: Acoustic imaging of the ocean 4Now in broadband: Acoustic imaging of the ocean 5Sports rehabilitation and injury prevention 2
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Assay Diluent Trial Pack, 4 x 100 mL...
... Immunogen: Synthetic peptide derived from the ... Specificity: Specific for the internall ... Reactivity: Mouse (positive controls: mouse brain ... tissues). Applications: Western blotting Immunohistochemistry(froz) ...
Rabbit anti-Junctophilin-4 (C-term)...
Biology Products: